Cash Flow Shenanigans

The numbers that should be hardest to fake

Cash flow from operations (CFFO) is supposed to be the honest counterpart to accrual earnings — real money in, real money out. Many investors treat it as the ultimate reality check. Schilit warns that this faith is misplaced: companies have found creative ways to inflate CFFO just as aggressively as they inflate earnings.

The playbook has three main chapters: recording bogus CFFO from bank borrowings, boosting CFFO by selling receivables early, and faking receivable sales entirely. Each shifts financing inflows into the Operating section of the Statement of Cash Flows.

Technique 1: Bogus CFFO from bank borrowings

At the end of 2000, auto-parts supplier Delphi Corporation faced the prospect of reporting severely negative quarterly operating cash flow — a devastating blow for a company that highlighted CFFO in every earnings release. Delphi's solution was to "sell" $200 million in precious metals inventory to Bank One, with a pre-arranged agreement to buy it back weeks later at a small premium.

The economics were simple: this was a short-term loan, collateralized by inventory. The cash should have been recorded as a Financing inflow. Instead, Delphi brazenly booked it as a sale of inventory, inflating both revenue and CFFO. Without the sham transaction, Delphi's full-year CFFO would have been just $68 million rather than the $268 million it reported, and the fourth quarter alone would have been negative $158 million.

Bogus revenue may also signal bogus CFFO. Investors should understand that one often travels with the other. — paraphrased from Schilit

Enron played the same game at larger scale using off-balance-sheet special-purpose entities. These vehicles would borrow money (with Enron co-signing the loans), then use the cash to "purchase" commodities from Enron. Enron booked the inflows as Operating while ignoring the fact that cash was flowing in a circle. The trick inflated CFFO by billions.

Red flag checklist:

• Pro forma cash flow metrics that differ wildly from reported CFFO
• Complicated off-balance-sheet structures involving SPEs or VIEs
• Inventory transactions with financial institutions (banks don't buy inventory)

Technique 2: Selling receivables early

Companies legitimately sell accounts receivable to collect cash before customers pay — a standard financing technique. Accounting rules classify this cash as an Operating inflow because it represents collections from past sales. This gray area creates opportunities for abuse.

In 2004, Cardinal Health sold $800 million in customer receivables, which was the primary driver of its $971 million CFFO growth that quarter. The company disclosed the transaction clearly, but casual investors missed the point: this was a one-time acceleration, not a sustainable improvement in operations. Future quarters would have a "hole" where those collections should have been.

The warning sign was a massive swing on the Statement of Cash Flows: the change in accounts receivable went from a $488 million outflow (prior year) to a $622 million inflow — a $1.1 billion delta that had nothing to do with business improvement.

Other companies are far less transparent. Sanmina-SCI Corporation highlighted strong CFFO in its earnings release, then buried the fact that receivable sales drove the result in a 10-K filed nearly two months later, on December 29 — while investors were on holiday. Without the increase in receivables sold, CFFO would have been $36 million instead of $175 million.

Red flag checklist:

• Sudden large swings in the receivables line of the cash flow statement
• Disclosures about factoring or securitization programs in footnotes
• CFFO strength that coincides with receivable declines (but revenue isn't declining)

Technique 3: Faking receivable sales

This is where the line crosses from aggressive into fraudulent. Peregrine Systems, already recording bogus revenue, transferred bloated receivables to a bank in exchange for cash — but the risk of collection loss never actually transferred. Since many of the underlying "sales" were fictitious, those receivables would never be collected, and Peregrine remained on the hook to return the money. Economically it was a collateralized loan; on paper it was booked as an Operating inflow.

The cover-up left traces. Peregrine's risk factor disclosure changed twice in 2001 — first mentioning new "customer financing" and collection difficulties, then adding a cryptic twelve-word sentence:

The Company may at times market certain client receivable balances without recourse.

Investors who compared filings quarter-to-quarter would have spotted these changes. Most didn't.

Computer Associates played a similar game after recording over $3.3 billion in premature revenue. Its FY 2000 10-K casually mentioned a fourth-quarter "decision" to assign receivables to a third party, with no details on mechanics or magnitude. Vitesse Semiconductor was caught only by accident — when a board committee investigating stock-option backdating stumbled onto evidence of sham receivable sales to Silicon Valley Bank.

Red flag checklist:

• Changes in risk-factor language between filings (use word-compare tools)
• Vague disclosures about "assigning" or "marketing" receivables
• New financing arrangements for customers that appear suddenly
• Receivable balances that stay stable despite revenue problems

Boomerang transactions: the full-circle trick

Global Crossing sold future network capacity to telecom peers while simultaneously buying similar capacity back from them — the corporate equivalent of trading dollars. The cash received was booked as an Operating inflow; the cash paid was buried as an Investing outflow. This inflated CFFO while depressing a metric nobody watched.

In 2000, Global Crossing reported $911 million in positive CFFO despite losing $1.7 billion. The company filed for bankruptcy in January 2002, just six months after selling $183 million in receivables to window-dress its cash position.

The boomerang test: when a company both buys from and sells to the same counterparty in roughly equal amounts, and the cash flows land in different sections of the SCF — something is wrong.

The detective's toolkit

Quick check

What you now know

• CFFO is not immune to manipulation — three main techniques shift financing inflows into the Operating section
• Sham inventory sales to banks are economically loans and should be classified as Financing
• Selling receivables is legitimate but can be a one-time CFFO accelerator that leaves a hole in future periods
• Fake receivable sales hide both bogus revenue and bogus CFFO behind collateralized loans
• Boomerang transactions inflate CFFO by routing matching inflows and outflows to different SCF sections
• Changes in risk-factor language, sudden receivable swings, and opaque off-balance-sheet structures are the primary warning signs

Next: Earnings Quality — how DSO, unbilled receivables, and the gap between CFFO and net income reveal aggressive revenue recognition before the restatement hits.